IDH1 and glioblastoma: Indeed, GSK864, a compound initially identified as a potent inhibitor of mutant IDH1 in AML [82], inhibits wild-type IDH1 activity, reduces GBM stem-like cell frequency and increases survival of tumor-bearing mice.